Clarient, Inc. at the 2010 OneMedForum
Written on Jan 29, 2010
Ron Andrews, CEO of Clarient, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San...
Strategic Medicine at the 2010 OneMedForum
Written on Jan 29, 2010
Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San...
TapImmune, Inc. at the 2010 OneMedForum
Written on Jan 29, 2010
Denis Corin, President of TapImmune, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San...
Jeff Eliot Margolis CFO of Xintria Pharmaceutical Corporation
Written on Jan 29, 2010
Jeff Eliot Margolis, CFO of Xintria Pharmaceutical Corporation, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San...
Echo Therapeutics Rated Strong Spec Buy by Life Tech Capital
Written on Jan 28, 2010
Over at Seeking Alpha, Mike Havrilla reports that biotechnology company Echo Therapeutics was rated a “strong speculative buy” by research and consulting firm LifeTech Capital. The following excerpt is from LifeTech’s Institutional Research Report on Echo:
There are a limited number of...
[OneMedForum] Biomoda’s Platform for Early Cancer Detection
Written on Jan 25, 2010
It’s common knowledge that cancer is more treatable in its early stages. One study published in the New England Journal of Medicine found that the early detection of lung cancer increased the five-year survival rate to from 15 to 92 percent. Unfortunately, many cancers are not discovered in time....
Genomic Health’s Colon Cancer Test Goes Worldwide
Written on Jan 24, 2010
Genomic Health, a developer of genomics-based diagnostic tests, announced on Thursday the worldwide availability of its Oncotype DX colon cancer test. Oncotype DX is the first multigene expression test designed to assess the risk of recurrence in patients with stage II colon cancer. The test may...
Ampyra Walks Away with FDA Approval
Written on Jan 22, 2010
The U.S. Food and Drug Administration (FDA) has approved the first drug designed to improve walking in adults with multiple sclerosis. Ampyra will be manufactured under licenses by Elan Pharma and distributed starting in March by Acorda Therapeutics. In clinical trials, patients who took Ampyra had faster...
